VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | MajesTEC-4: teclistamab + lenalidomide vs lenalidomide as maintenance therapy in NDMM

Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, comments on the recent approval of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma, and outlines the design of MajesTEC-4 (NCT05243797), a Phase III trial that will evaluate the benefits of teclistamab in combination with lenalidomide versus lenalidomide alone as maintenance therapy after autologous transplantation in patients with newly diagnosed multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter